Australian-New Zealand Clinical Trial: A Phase 1b, Open-Label Dose-Escalation Study of Sapu006 in Patients with Advanced Solid Tumors Selected by Baseline Serum Albumin, with Exploratory Tumor Albumin (ALB) RNA Profiling

Australia, Nov. 6 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘A Phase 1b, Open-Label Dose-Escalation Study of Sapu006 in Patients with Advanced Solid Tumors Selected by Baseline Serum Albumin, with Exploratory Tumor Albumin (ALB) RNA Profiling’. The following are the other relevant details related to the trial:

Trial ID: 392861

Submit Date: 10/19/26 21:33

Study Type: Interventional

Intervention: SAPU006 (a polymer-based, solvent-free nanoparticle formulation of docetaxel) is given as an intravenous infusion over 60 minutes (±5 minutes) on Day 1 of each 21-day cycle (every 3 weeks). Participants are enrolled into 2 cohorts. In Cohort 1, participants with metastatic bre...